Quality of life in patients with rheumatoid arthritis during rituximab therapy
https://doi.org/10.14412/1996-7012-2013-2383
Abstract
Objective: to evaluate the effect of rituximab (RTM) on quality of life (QL) in patients with rheumatoid arthritis (RA) from the results of EQ-5D questionnaire total scores. Subjects and methods. Ninety-eighty patients with a valid diagnosis of RA were followed up. All the patients were randomized to two groups according to the basic therapy option: 1) 56 patients on combination therapy with methotrexate (MT; mean dose 13.72±0.06 mg weekly) and rituximab (RTM) by the standard regimen; 2) 42 patients receiving only MT (mean dose 12.6±0.08 mg weekly). The follow-up was 24 months. The international EQ-5D questionnaire was employed to assess QL. Results. While filling out the EQ-5D questionnaire, all the patients with RA mentioned baseline health problems to one extent or another. One year after therapy, there was a statistically significant increase in health index in both Groups 1 and 2: 0.61±0.04 and 0.63±0.07 (р<0.05 and р<0.05, respectively). Group 1 showed a statistically significant rise in VAS scores at 12 (46.7±6.3 mm; р<0.05) and 24 (49.3±11.4 mm; р<0.05) months versus at baseline. Conclusion. There was a satisfactory therapeutic effect only in the MT + RTM combination group whereas there was a minimal one in the MT monotherapy group.
References
1. <div><p>Амирджанова В.Н. Качество жизни больных ревматоидным артритом, получающих ритуксимаб. Науч-практич ревматол 2008; 1(прил):15-20.</p><p>Staquet M.J. Quality of life assessment in clinical trials. Oxford University Press, 1998;360.</p><p>Spilker B. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: New York:Lippincott-Raven, 1996;1259.</p><p>World Health Organization. The constitution of the World Health Organization. WHO Chron 1947;1:29.</p><p>Насонов Е.Л. Ритуксимаб в лечении ревматических болезней. Науч-практич ревматол 2008;1(прил): 1:3-10.</p><p>Лукина Г.В., Сигидин Я.А., Кузикянц К.Х. и др. Опыт применения ритуксимаба у больных ревматоидным артритом в реальной клинической практике по данным Российского регистра АРБИТР. РМЖ 2011;25:1518.</p><p>Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. М.: ИМА-Пресс, 2012;344 с.</p><p>Cohen S.B., Emery P., Greenwald M.W. et al. for the REFLEX Trial Group. Rituximab for the rheumatoid arthritis refractory to antitumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr Rheum 2006;54:2793-806.</p><p>Emery P., Fleishmann R., Filipowich-Sosnowska A. et al. for the DANCER study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arthr Rheum 2006;54:1390-400.</p><p>Воробьев П.А. Клинико-экономический анализ. М., 2004.</p><p>Salaffi F., de Angelis R., Stancati A. et al. Clin Exp Rheum 2005;23(6):829-39.</p><p>Symmons D., Tricker K., Roberts C. et al. Health Technol Assess 2005;9(34):III—IV:1—78.</p></div><br />
Review
For citations:
Raskina TA, Koroleva MV. Quality of life in patients with rheumatoid arthritis during rituximab therapy. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2013;7(2):57-61. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2383
Views:
1756
Email this article 